Table 2

Association between FGFR-4 genotype pathological parameters in white patients

FGFR-4 genotypeGA/AA (%)P2)
Gly/Gly (%)Gly/Arg (%)Arg/Arg (%)
Gleason score (N = 283)n = 125n = 117n = 41n = 158
 5, 612057 (48)46 (38)17 (14)63 (52)
 7–916368 (42)71 (44)24 (15)95 (59)0.33
Pathological stage (N = 280)n = 123n = 116n = 41n = 157
 T215573 (47)61 (39)21 (14)82 (53)
 T312550 (40)55 (44)20 (16)75 (60)0.23
LN metastasis (N = 283)n = 125n = 117n = 41n = 158
 (−)262120 (46)104 (40)38 (14)142 (54)
 (+)215 (24)13 (62)3 (14)16 (76)0.04
PSA recurrence (N = 244)n = 104n = 105n = 35n = 140
 (−)17181 (47)70 (41)20 (12)90 (53)
 (+)7323 (31)35 (48)15 (21)50 (69)0.02
  • NOTE. FGFR-4 genotype was determined by PCR-RFLP as described in Materials and Methods. The T stage is the pathological stage based on the American Joint Committee on Cancer staging system for prostatectomy specimens. The presence of lymph node (LN) metastasis was determined by pelvic lymph node dissection at the time of radical prostatectomy. The percentage of patients with the given genotype is indicated in parentheses. Assessment of the difference in frequency of the Gly/Gly genotype versus the combined Gly/Arg and Arg/Arg groups was done by Pearson’s χ2 test.